Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study
Status:
Terminated
Trial end date:
2017-03-02
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the effectiveness and safety of human immunoglobulin
SCIg in the form of Hizentra (Immune globulin Subcutaneous) in patients with Dermatomyositis.
Hizentra provides effective protection against infection by maintaining a steady and normal
level of immunoglobulin in the body) in patients with primary immunodeficiency. At present,
patients with steroid resistant dermatomyositis can only be treated with IVIg (The healthy
antibodies in IVIG can block the damaging antibodies that attack muscle and skin in
dermatomyositis) treatment. An evaluation can then be made to see if SCIg is a suitable
replacement and exerts immunomodulatory effect on complement antibodies.